
Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2012

Terumo Corporation July 28, 2011

Consolidated Q1 Results

Marked an excellent start for dramatic growth (billions of yen)

	, and the second		
	Q1 Mar. 2011	Q1 Mar. 2012 ^(*)	YoY%
Net Sales	81.2	95.6	+18%
Gross Profit	42.3 (52.1%)	50.9 (53.2%)	+20%
SG&A Expenses	26.4 (32.5%)	33.5 (35.0%)	+27%
Operating Income (Excl. Amortization of goodwill)	15.9 (19.6%) 16.4 (20.1%)	17.4 (18.2%) 19.3 (20.2%)	+9% +18%
Ordinary Income	12.6 (15.5%)	16.9 (17.6%)	+34%
Net Income	8.8 (10.8%)	9.8 (10.2%)	+11%
Average Exchange Rate	US\$ 92yen EUR 117yen	82yen 117yen	





Consolidated Q1 Results (Pro-forma comparison)

Increase both in sales & income even at Pro-forma comparison

(billions of yen)

	Corresponding period of last yr Pro-forma basis *1	Q1 Mar. 2012	YoY%	Excluding Foreign Exchange
Net Sales	93.1	95.6	+3%	+7%
Gross Profit	49.7 (53.4%)	50.7 (53.0%)	+2%	+8%
SG&A Expenses	30.8 (33.1%)	30.9 (32.3%)	+0%	+5%
Operating Income (Excl. impact of acquisition *2)	18.9 (20.3%)	19.8 (20.7%)	+5%	+13%
Average Exchange Rate	US\$ 92yen EUR 117yen	82yen 117ven		

(*1) Including BCT and Harvest results

(*2) Excluding newly accrued amortization of goodwill and intangible assets



Q1 Results of BCT Stand Alone

Favorable start after acquisition

	Q1 Mar. 2012	YoY% (Excluding Foreign Exchange)
Net Sales	11.9	+17%
Gross Profit	7.5 (62.4%)	+19%
SG&A Expenses	4.6 (38.5%)	+25%
Operating Income	2.9 (23.9%)	+10%
Ordinary Income	2.9 (24.4%)	
Net Income	1.8 (15.3%)	




Q1 Results of Existing Business

Steady increase both in sales & income


	Q1 Mar. 2011	Q1 Mar. 2012	YoY%	Excluding Foreign Exchange
Net Sales	81.2	83.4	+3%	+6%
Gross Profit	42.3 (52.1%)	43.0 (51.6%)	+2%	+6%
SG&A Expenses	26.4 (32.5%)	26.0 (31.3%)	-1%	+2%
Operating Income	15.9 (19.6%)	17.0 (20.3%)	+6%	+13%
Ordinary Income	12.6 (15.5%)	16.4 (19.7%)	+31%	
Net Income	8.8 (10.8%)	10.4 (12.5%)	+18%	

Net Sales (by Region)






Net Sales (by Business Segment)



Gross Profit Variance Analysis





Excluding BCT & Harvest

SG&A Expenses

(billions of yen)

	Q1 Mar. 2011	Q1 Mar. 2012	YoY	YoY%
Salaries & Wages	9.8	9.8	+0	+1%
Sales Promotion	2.6	2.6	-0	-1%
Logistical Costs	2.3	2.5	+2	+7%
Depreciation & Amortization	1.1	1.0	-1	-7%
Others	5.7	5.8	+1	+3%
General Administrative Total	21.5 (26.5%)	21.7 (26.2%)	+2	+1%
R&D Expenses	4.9 (6.0%)	4.3 (5.1%)	-6	-13%
SG&A Expenses Total	26.4 (32.5%)	26.0 (31.3%)	-4	-1%




() %: Against net sales

Consolidated B/S after BCT Acquisition

■ Purchase Price Allocation for BCT
■ Terumo group B/S after consolidation

Purchase price	210.0 b	oillion yen
Working capital	5.6	
Acquisition price	215.6	→ B/S of BCT Stand Alone
BCT assets	35.7)
BCT liabilities	-11.4	
Intangible asset	117.4	Consolidated
Deferred tax liabilities	-45.3	B/S
Goodwill	ر 119.2)
Total	215.6 b	oillion yen
(US\$ = 80JPY)		



Total 693.6 billion yen Total 693.6 billion yen



Forecast for Mar 31, 2012

Double-digit growth both in sales & income

		Revised Forecast			
	Original Forecast (Excl. BCT & Harvest)	Existing Businesses	YoY%	Consolidated (Incl. BCT & Harvest)	YoY%
Net Sales	332.0	340.5	+4%	390.0	+19%
Operating Income	65.0 (19.6%)	67.0 (19.7%)	+7%	67.0 (17.2%)	+7%
Ordinary Income	63.0 (19.0%)	65.0 (19.1%)	+14%	65.0 (16.7%)	+14%
Net Income	40.0 (12.0%)	40.8 (12.0%)	+26%	38.5 (9.9%)	+19%
Operating Income Income Net Income	66.5 (20.0%)	68.5 (20.1%)	+7%	74.6 (19.1%)	+16%
Amortization Net Income	41.5 (12.5%)	42.3 (12.4%)	+25%	46.1 (11.8%)	+36%
TERUMO			2011/7/28	©Terumo Corporation	11/21

Topics


Nobori[™] DES: Launched in Japan

Expected New Products Launch

Nobori™

Targeting Sales of 20 billion yen

Nobori[™] Sales Performance




Gained 30% JP mkt share (value base) in 2 mos after the launch



New Products Launch To Be Doubled





Mar. 2012

(Forecast)

- > DuraHeart™ Left Ventricular Assist System
- > New bare embolization coil for cerebral aneurysm
- First-in-JP Glucose Monitor which links to EMR
- ▶ PG Water™ Rehydrating Water Jelly type
- New IV catheter



<Outside of Japan>

- ➤ KYMERAXTM Precision-drive articulating surgical system (EU)
- Infusion pump designed for China and Asia
- Next generation vascular graft (self-sealing)



Strive further growth by continuous new products launch



Mar. 2011

Establishing a Holding Company in China

TERUMO (China) Holdings Co., Ltd.: Approved to establish in Beijing (Jul 18)

- > Strengthen business base, incl. local development, production, and sales
- > Establish additional 4 sales offices in addition to current 8 sales offices
 - Changchung Factory
 - TERUMO (China) Holdings Co., Ltd.

- New Sales Office
- Current Sales Office

- Terumo Medical (Shanghai) Co., Ltd.
- Hangzhou Factory

Target to double Sales to 20 billion yen in FY2013

Reference



Impact of BCT & Harvest to Consolidated Operating Income

	Forecast Mar. 2012
Net Sales (BCT & Harvest)	49.5
Operating Income (BCT & Harvest)	9.2
Amortization of goodwill	-6.1
Amortization of newly accrued intangible assets	-3.1
Impact to consolidated Operating Income	0




Q1 Results To 1st Half Forecast

	1H Forecast	Q1 Results	<u>Progress</u>
Net Sales	191.0	95.6	50%
Operating Income	32.7 (17.1%)	17.4 (18.2%)	53%
Ordinary Income	31.5 (16.5%)	16.9 (17.6%)	54 %
Net Income	18.5 (9.7%)	9.8 (10.2%)	53%
Average exchange rate	S		
(US\$)	80 yen	82 yen	
(EUR)	113 yen	117 yen	




BCT & Harvest Gross Profit, SG&A Expenses, Operating Income



(Quarterly: 3 months)

Changes of Quarterly Average Exchange Rates



(Quarterly: 3 months)



IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.

